{"name":"European Lung Cancer Working Party","slug":"european-lung-cancer-working-party","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Adriamycin, cyclophosphamide, vindesine, valproic acid","genericName":"Adriamycin, cyclophosphamide, vindesine, valproic acid","slug":"adriamycin-cyclophosphamide-vindesine-valproic-acid","indication":"Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"Cisplatin + etoposide","genericName":"Cisplatin + etoposide","slug":"cisplatin-etoposide","indication":"Small cell lung cancer","status":"phase_3"},{"name":"Cisplatin, Ifosfamide, Gemcitabine","genericName":"Cisplatin, Ifosfamide, Gemcitabine","slug":"cisplatin-ifosfamide-gemcitabine","indication":"Lung cancer (non-small cell lung cancer)","status":"phase_3"},{"name":"Epirubicin + ifosfamide + etoposide","genericName":"Epirubicin + ifosfamide + etoposide","slug":"epirubicin-ifosfamide-etoposide","indication":"Small cell lung cancer (phase 3 trial)","status":"phase_3"},{"name":"Ifosfamide, Gemcitabine","genericName":"Ifosfamide, Gemcitabine","slug":"ifosfamide-gemcitabine","indication":"Lung cancer (phase 3 trial setting)","status":"phase_3"}]}],"pipeline":[{"name":"Adriamycin, cyclophosphamide, vindesine, valproic acid","genericName":"Adriamycin, cyclophosphamide, vindesine, valproic acid","slug":"adriamycin-cyclophosphamide-vindesine-valproic-acid","phase":"phase_2","mechanism":"Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression.","indications":["Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer","Multiple myeloma"],"catalyst":""},{"name":"Cisplatin + etoposide","genericName":"Cisplatin + etoposide","slug":"cisplatin-etoposide","phase":"phase_3","mechanism":"Cisplatin and etoposide work together as a chemotherapy combination: cisplatin cross-links DNA to prevent replication, while etoposide inhibits topoisomerase II to block DNA unwinding and repair.","indications":["Small cell lung cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Cisplatin, Ifosfamide, Gemcitabine","genericName":"Cisplatin, Ifosfamide, Gemcitabine","slug":"cisplatin-ifosfamide-gemcitabine","phase":"phase_3","mechanism":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","indications":["Lung cancer (non-small cell lung cancer)","Potentially other solid tumors under investigation"],"catalyst":""},{"name":"Epirubicin + ifosfamide + etoposide","genericName":"Epirubicin + ifosfamide + etoposide","slug":"epirubicin-ifosfamide-etoposide","phase":"phase_3","mechanism":"This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells.","indications":["Small cell lung cancer (phase 3 trial)"],"catalyst":""},{"name":"Ifosfamide, Gemcitabine","genericName":"Ifosfamide, Gemcitabine","slug":"ifosfamide-gemcitabine","phase":"phase_3","mechanism":"This combination of ifosfamide and gemcitabine uses two chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.","indications":["Lung cancer (phase 3 trial setting)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1VM0dzYWFGX2NreTQ2RUx4cU1GY25FVXlxNGh1RGx1alJFQWtUX2s2S0dMVWdJTVpBazZ5ODVYSjI0cjdHRHFwLVNfNHZsVGgzb2g3M1BySFdnVm1sbjBfbEpsY05PTXh4ckNRQjlwdG5Qdw?oc=5","date":"2025-12-11","type":"pipeline","source":"ec.europa.eu","summary":"Knowledge Centre on Cancer: Tackling Cancer and other Non-communicable diseases (NCDs) - ec.europa.eu","headline":"Knowledge Centre on Cancer: Tackling Cancer and other Non-communicable diseases (NCDs)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPYnN6RnNidllycmtlUVQtVEpWdWI1bVBLOUxpSm9rd3JpdEFPVUJCNXNHYlJmbi1pa29iREtFTURIR1FuVXBCbHFEQXNQbGxSRUROM1hhYVBSemtQREdMcmV6X0ZDc041eW9OVlFtcG1KTEgxa1BGLVhFajFhWHFyd01FTDlVa19wYmNDX1JtMW5mMEhXTWVHZms5RzJvc0E4VkhqWG9oUFhzR3Z6S0xKUFA1VnBQS3NkTzRST29n?oc=5","date":"2025-08-13","type":"earnings","source":"HMP Global Learning Network","summary":"Driving Change: What the PCC Working Group Has Learned and What’s Next - HMP Global Learning Network","headline":"Driving Change: What the PCC Working Group Has Learned and What’s Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE83bDFNazJuc0g2UENMeTVNemZia19ldU5SeHVDN3p3d3ZkMkZQejVKazhKS2YxTFcwWGdjc0k2bC1vMWx5Zl9qRFYwWklyX0phUkszc1VkMjB6Wmd0R25sSHhHbUVTUmJvRnRJ?oc=5","date":"2025-07-29","type":"pipeline","source":"ec.europa.eu","summary":"Human Medicines Highlights - February 2025 - ec.europa.eu","headline":"Human Medicines Highlights - February 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1QWnEweGMzUGU2dTNqNmlEVWV2NFNNNk5yckk0M3dtODAwdURnaTREOVltTWpWbzdhbjdxMzVWVVJqSlgtbGR1ejNMZ2N0Nmw0eFJyVXc5NDFybFFwVjRmN013?oc=5","date":"2025-07-25","type":"pipeline","source":"Time Magazine","summary":"Talc Is Suddenly in the Spotlight. Is it Bad for You? - Time Magazine","headline":"Talc Is Suddenly in the Spotlight. Is it Bad for You?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9yTUY1YXFyN2tTSlNNelUyaG0wMXIxMFpxNC03b2Uta05jMHdHcjNaWk9xVV9HQ3J4QXJxcHRnSzRIQ0dCMkt5NTJOMzlsa0NBZThEZmVjN25EaTQ2a1RicXh6Z2RreGtVaFhhdQ?oc=5","date":"2025-05-20","type":"pipeline","source":"Labiotech.eu","summary":"Seven lung cancer companies advancing new treatments in 2025 - Labiotech.eu","headline":"Seven lung cancer companies advancing new treatments in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxONElrdFZDSFZ6TG1Hekw3MzBSOWZZZ0Y1bF9CX3p0dVVidmkwblhDc1FmM1g4MlBrOXpYNlFmUXFXNkRpUi1sUWlUN1FkZjh4bEdKMy1nSDRJd056TnR4VVp3Q1J1Nlo4WkIwVFl6aEFFUmN5UWZyRmY5QThrTmJScEZ4RFNWTWoxWGREN0l0M1ZVNWtaODdZenhoVEVuMmczN0pRdFZOT3RQQ1h6bm1MYm5HSklTdURGWTJSQmhIMkRVdFBhYUdQR01FQndjNDFpazV6WA?oc=5","date":"2024-09-15","type":"pipeline","source":"Investigate Europe","summary":"Drug firms finance Europe’s patient groups with multi-million donations - Investigate Europe","headline":"Drug firms finance Europe’s patient groups with multi-million donations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNLVp0T05PanBzYU9jbi1ILWZkekxLaWxuMUFOSEFVZ2dZRUhZUUVMVldYNGdRNGYyOV80a2dERVdTYXJVa0RMcy1pMVdUbm04SWplVzMzTW8yN2Y1OGl0T2NURlJEWFVxbWR1VFdRT1l3eGNGY2doUkx0a3N1X2lnX1BROC10WWRQVzRkaTBXaTRKc3BDQXUwcG1GRmpCNll6eER6WURaNV9xaERyUzlYcHVJMUNvUi1RZ3Jnemt3SQ?oc=5","date":"2024-09-13","type":"pipeline","source":"fiercepharma.com","summary":"ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value from new cancer meds - fiercepharma.com","headline":"ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value from new cancer meds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBwZnJMN3JkY1NnSVVQU2lxaEtiQ2VtckFObXRPNU5PUUNyU21DWWJ1bkVwMU5HNWp4Mk4zbDR6ZHBteTJsakpGZzZzMk9yaXZUMlNRdGZWLXZvWXBDcU9V?oc=5","date":"2024-07-23","type":"trial","source":"Nature","summary":"Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplanta","headline":"Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 mult","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE92SGpRY2RCOUg2ZEJfWHVWb1dhT3hoZkNuRHkzQ2otaWRINEM1WVl0WjBka0syOVRlTlBEd2Ffc0tqbEFDSmNjOEJod04xOV9lTjFiRnZmcXZJMy1jNWcw?oc=5","date":"2024-01-03","type":"regulatory","source":"Nature","summary":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports - Nature","headline":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRko4X0FlMUw3N0d5ZmQzVVZuV1lyX2dZUGxKM2Zqd3hIQWtueXNSSUVTYVpFb0lwVjdnZl9HdVVEMG1jVG9odmZoS3loTExsWllsYVJmX2FoY3R6bU1kZlF5M182b0FYdjdNM0NITzNxYzJWNUIwVElBTnpVanZ6QUdoaGVNUDZsOGotWE1rN0lVbmw0WU5PQTV6a2pSb0hNWE9LWXFMOU5oQi1MTHZhQmhoM3N1eXJQSDd4dU5VVjU?oc=5","date":"2023-09-06","type":"regulatory","source":"ESMO Daily Reporter","summary":"Anti-cancer medicines are typically approved in the USA eight months before Europe - ESMO Daily Reporter","headline":"Anti-cancer medicines are typically approved in the USA eight months before Europe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOM0dkbG4xbHhPamFJdTRtZjY1RTJLMkI1bEU1bV93bDgwcVFQWFVMeWxHckVTTXprMmcxNFAtcEx4SkNTWlBpWE1PWHNKaG8tMldRbjRiMml3Q2g3THdlQW04TFlYNklhRk5BNDM5RWQ3QzNXRzdzZEVDQW9CNVZvSVFQV2xyZmRZNjRJd3cxTHdPODZ1UzA0SEdFLWNlWHZPbGVWT1oybmFOeDZFWjZDRW5uanRYUi1HNnZ3?oc=5","date":"2023-05-17","type":"pipeline","source":"Reuters","summary":"EU, United States launch joint health task force - Reuters","headline":"EU, United States launch joint health task force","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFByY2tIQnRCU0lEZXdQLTY5NFB4WXREWWdSdk9CR0tEQWJxVkFMX20xYlJvRnF0Wk5kNTZfdjd3Y2Y1Wm9KTVRPTXhGMHpvMHN6WW9YekdkUk94bHRGQ2diclNfeERqRzVleWg5NXl0b3J0WDA?oc=5","date":"2020-03-23","type":"pipeline","source":"American Heart Association Journals","summary":"Research Priorities for Heart Failure With Preserved Ejection Fraction | Circulation - American Heart Association Journals","headline":"Research Priorities for Heart Failure With Preserved Ejection Fraction | Circulation","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":1,"phase_3":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}